🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,067 results for “Hospital” Clear

  1. Routine Template-based lymphadenectomy

    The First People's Hospital of Lianyungang

    Lymph Node Dissection

    phase 2 other active

    1 trial

  2. Roxadustat

    Peking University Third Hospital

    Coronary Artery Bypass

    phase 2 small molecule terminated

    1 trial

  3. Ruxolitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    aGVHD

    phase 2 small molecule completed

    1 trial

  4. Ruxolitinib

    The First People's Hospital of Lianyungang

    Bronchiolitis Obliterans Syndrome

    phase 2 small molecule active

    1 trial

  5. Ruxolitinib 5 MG BID Oral Tablet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA

    phase 2 small molecule active

    1 trial

  6. S1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  7. S1RA plus NMDAE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule active

    1 trial

  8. SBRT combined with Nimotuzumab followed by Tislelizumab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Cancinoma (NPC)

    phase 2 small molecule active

    1 trial

  9. SBRT combined with PD-1 inhibitors and thoracic hyperthermia

    The First People's Hospital of Lianyungang

    Stereotactic Body Radiation Therapy; PD-1 Inhibitor; Hyperthermia; NSCLC

    phase 2 other active

    1 trial

  10. SBRT combined with Tislelizumab followed by Tislelizumab

    Zibo Municipal Hospital

    NSCLC

    phase 2 small molecule active

    1 trial

  11. SG+I

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    TNBC, Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  12. SHR-1139 Injection

    The First People's Hospital of Lianyungang

    Pyoderma Gangrenosum

    phase 2 small molecule active

    1 trial

  13. SHR-1210

    The First People's Hospital of Lianyungang

    Resectable Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  14. SHR-1210

    Hospital Authority, Hong Kong

    Renal Cell Carcinoma

    phase 2 mab active

    1 trial

  15. SHR-1701

    The First People's Hospital of Lianyungang

    Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  16. SHR-1701 Combined With Fluazopalil

    Hunan Province Tumor Hospital

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  17. SHR-A1921 injection and adebrelimab injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    NSCLC

    phase 2 small molecule active

    1 trial

  18. SHR2554/AZA + Overlapped TBF

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 other active

    1 trial

  19. SKB103 for injection monotherapy

    Sichuan Provincial People's Hospital

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  20. SNUBH-NM-333(18F)

    Hospital Authority, Hong Kong

    Alzheimer Disease

    phase 2 other terminated

    1 trial

  21. SOX Chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  22. SS-1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Sjögren's Syndrome

    phase 2 small molecule active

    1 trial

  23. SS-1

    Hospital Authority, Hong Kong

    Sjögren's Syndrome

    phase 2 small molecule active

    1 trial

  24. Sacituzumab Tirumotecan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Extensive-Stage Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources